Basic Information
LncRNA/CircRNA Name | PVT1 |
Synonyms | PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100 |
Region | GRCh38_8:127794533-128101253 |
Ensemble | ENSG00000249859 |
Refseq | NR_003367 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | bladder urothelial cancer |
ICD-0-3 | NA |
Methods | qPCR, Western blot, Luciferase reporter assay etc. |
Sample | cell lines (BUC, J82 and T24) |
Expression Pattern | up-regulated |
Function Description | lncRNA PVT1 is overexpressed in multidrug resistant BUC tissues and cell lines, and PVT1 knockdown reduces BUC cell proliferation, invasiveness, and chemoresistance by modulating Wnt/B-catenin signaling. PVT1 was upregulated in BC, where it promoted tumor cell proliferation and suppressed apoptosis. |
Pubmed ID | 28969069 |
Year | 2017 |
Title | LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. |
External Links
Links for PVT1 | GenBank HGNC NONCODE |
Links for bladder urothelial cancer | OMIM COSMIC |